| Autor: |
Louis, Edouard, Resche-Rigon, Matthieu, Laharie, David, Satsangi, Jack, Ding, Nik, Siegmund, Britta, D'Haens, Geert, Picon, Laurence, Bossuyt, Peter, Vuitton, Lucine, Irving, Peter, Viennot, Stephanie, Lamb, Christopher A, Pollok, Richard, Baert, Filip, Nachury, Maria, Fumery, Mathurin, Gilletta, Cyrielle, Almer, Sven, Ben-Horin, Shomron, Bouhnik, Yoram, Colombel, Jean-Frederic, Hertervig, Erik, Andrews, Jane, Sparrow, Miles, Leong, Rupert, Connor, Susan, Radforth-Smith, Graham, De Cruz, Peter, Preiss, Jan, Stallmach, Andrea, Liceni, Thomas, Grip, Olaf, Halfvarson, Jonas, Durai, Dharmaraj, Cummings, Fraser, Seilinger, Christian, Parkes, Miles, Lindsay, James, Lambrecht, Guy, Van Hootegem, Philippe, Rahier, Jean-François, Dewitte, Marie, Hebuterne, Xavier, Chanteloup, Elise, Altwegg, Romain, Nancey, Stephane, Bouguen, Guillaume, Pineton de Chambrun, Guillaume, Poullenot, Floriant, Roblin, Xavier |
| Zdroj: |
The Lancet Gastroenterology & Hepatology; March 2023, Vol. 8 Issue: 3 p215-227, 13p |
| Abstrakt: |
The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our aim was to compare the relapse rate and the time spent in remission over 2 years between patients continuing combination therapy and those stopping infliximab or immunosuppressant therapy. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
